Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor
journal contributionposted on 22.02.2017, 00:00 by Stefano Tomassi, Jonas Lategahn, Julian Engel, Marina Keul, Hannah L. Tumbrink, Julia Ketzer, Thomas Mühlenberg, Matthias Baumann, Carsten Schultz-Fademrecht, Sebastian Bauer, Daniel Rauh
The specific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthrough in targeted cancer therapy and marks a drastic change in the treatment of non-small cell lung cancer (NSCLC). The recurrent emergence of resistance to these targeted drugs requires the development of novel chemical entities that efficiently inhibit drug-resistant EGFR. Herein, we report the optimization process for a hit compound that has emerged from a phenotypic screen resulting in indazole-based compounds. These inhibitors are conformationally less flexible, target gatekeeper mutated drug-resistant EGFR-L858R/T790M, and covalently alkylate Cys797. Western blot analysis, as well as characterization of the binding kinetics and kinase selectivity profiling, substantiates our approach of targeting drug-resistant EGFR-L858R/T790M with inhibitors incorporating the indazole as hinge binder.
Read the peer-reviewed publication
non-small cell lung cancernovel chemical entitiesbinding kineticskinase selectivitycovalently alkylate Cys 797.target gatekeeperTarget Drug-Resistant Epidermal Growth Factor Receptoroptimization processepidermal growth factor receptorinhibitorphenotypic screenNSCLCdrug-resistant EGFRblot analysisindazole-based compoundsdrug-resistant EGFR-L 858RIndazole-Based Covalent Inhibitorscancer therapy